BOSTON, July 7, 2021 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology firm targeted on the invention, growth, and commercialization of novel therapies for illnesses involving mitochondrial dysfunction, at this time introduced that it has joined the Rare Disease Company Coalition, an alliance of life science corporations dedicated to discovering, creating, and delivering uncommon illness remedies for the sufferers they collectively serve.
“We’re thrilled to be part of the first-of-its-kind Uncommon Illness Firm Coalition, which is targeted on supporting uncommon illness sufferers by way of the event of revolutionary therapeutics,” mentioned Reenie McCarthy, Chief Govt Officer at Stealth. “We sit up for working with the opposite inspiring corporations to foster larger understanding of the distinctive challenges and circumstances related to the event of uncommon illness remedies.”
The Coalition will have interaction with coverage stakeholders to advocate for impactful drug and healthcare insurance policies and rules presently below dialogue, together with prescription drug pricing, to focus on the results that blanket laws can have on continued innovation for uncommon illness remedies.
About Uncommon Illness Firm Coalition
The Uncommon Illness Firm Coalition represents life science corporations dedicated to discovering, creating and delivering uncommon illness remedies for the sufferers we serve. As an schooling and advocacy-focused coalition of corporations, our objective is to tell policymakers of the distinctive challenges and guarantees of uncommon illness drug discovery, growth and manufacturing for small inhabitants sizes to ensure that important innovation to proceed. To attain this objective, we’ll use our unified voice to advocate for long-term, constant, equitable and sustainable authorities insurance policies that allow life science corporations to proceed to deliver hope and supply entry to accepted remedies to folks dwelling with uncommon illnesses. For extra info, please go to rarecoalition.com
We’re a clinical-stage biotechnology firm targeted on the invention, growth, and commercialization of novel therapies for illnesses involving mitochondrial dysfunction. Mitochondria, present in almost each cell within the physique, are the physique’s fundamental supply of vitality manufacturing and are important for regular organ operate. Dysfunctional mitochondria characterize numerous uncommon genetic illnesses and are concerned in lots of frequent age-related illnesses, usually involving organ programs with excessive vitality calls for comparable to the guts, the attention, and the mind. We consider our lead product candidate, elamipretide, has the potential to deal with each uncommon metabolic cardiomyopathies, comparable to Barth, Duchenne muscular dystrophy and Friedreich’s ataxia, uncommon mitochondrial illnesses entailing nuclear DNA mutations, in addition to ophthalmic illnesses entailing mitochondrial dysfunction, comparable to dry age-related macular degeneration and Leber’s hereditary optic neuropathy. We’re evaluating our second-generation clinical-stage candidate, SBT-272, and our new sequence of small molecules, SBT-550, for uncommon neurological illness indications following promising preclinical knowledge. We now have optimized our discovery platform to establish novel mitochondria-targeted compounds which can be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to ship different compounds to mitochondria.
Stern Investor Relations
Janhavi Mohite, 212-362-1200
SOURCE Stealth BioTherapeutics Inc.